Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up – Should You Buy?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $18.73, but opened at $19.53. Adaptive Biotechnologies shares last traded at $18.0950, with a volume of 745,246 shares.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ADPT. Morgan Stanley lowered their price objective on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. BTIG Research reiterated a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. TD Cowen increased their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.57.

Adaptive Biotechnologies Stock Performance

The company’s fifty day moving average is $14.57 and its 200-day moving average is $15.68. The company has a market capitalization of $2.82 billion, a PE ratio of -53.33 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. The company had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.20) EPS. On average, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Francis Lo sold 39,741 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $17.49, for a total transaction of $695,070.09. Following the completion of the sale, the insider directly owned 250,934 shares of the company’s stock, valued at $4,388,835.66. This trade represents a 13.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 11,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $18.00, for a total transaction of $198,000.00. Following the completion of the transaction, the insider directly owned 416,775 shares of the company’s stock, valued at approximately $7,501,950. This trade represents a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 516,654 shares of company stock valued at $7,509,691. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Ameriprise Financial Inc. grew its holdings in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after purchasing an additional 3,299,635 shares during the last quarter. Westfield Capital Management Co. LP bought a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth $65,942,000. Geode Capital Management LLC lifted its position in shares of Adaptive Biotechnologies by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after purchasing an additional 110,825 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Adaptive Biotechnologies by 3.3% during the fourth quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after buying an additional 102,362 shares during the period. 99.17% of the stock is owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.